Publications by M Novosadova

Publications by authors named "M Novosadova"

Eur J Heart Fail

December 2024

The study aimed to understand the outcomes of patients experiencing worsening heart failure (WHF) while receiving outpatient treatment and to identify factors linked to poor responses to loop diuretics.
Between September 2022 and March 2023, 44 patients with WHF symptoms were monitored weekly; improvements in symptoms and quality of life were noted, but certain biomarkers indicated a risk for poor diuretic response.
High levels of cystatin C, NT-proBNP, and troponin T were found to be strong indicators of inadequate response to fluid treatment in these patients, suggesting a need for alternative therapies for those affected.

ESC Heart Fail

October 2024

Cardiogenic shock (CS) poses significant health risks, necessitating effective interventions to maintain blood pressure and tissue perfusion, while current treatments, like inotropes, can lead to serious side effects.
The SEISMiC study aims to evaluate the safety and effectiveness of istaroxime, a new drug that may improve blood flow without overstimulating adrenergic receptors, in patients at risk for CS.
This multinational, double-blind study involves patients with severe heart failure and aims to measure the drug's impact on blood pressure and other cardiac metrics over a 60-hour period, aiming to clarify istaroxime's potential benefits in managing pre-CS conditions.

J Card Fail

September 2024

A study looked at how steroids, like prednisone, help reduce congestion in patients with acute heart failure (AHF).
Patients taking prednisone showed more improvement in their congestion levels compared to those receiving regular care.
The results suggest that steroids can help with symptoms related to congestion, but more research is needed to confirm these findings.

Clin Res Cardiol

November 2024

- Anemia is a common issue among heart failure patients, affecting their treatment outcomes, and this study aimed to examine how anemia prevalence changes and its relationship with clinical results in heart failure patients from the STRONG-HF study.
- In the study of 1077 patients, anemia rates rose from 27.2% at enrollment to 32.1% at 90 days, with a slightly higher primary composite outcome observed in anemic patients, but the difference wasn't statistically significant.
- Patients with baseline anemia showed less improvement in health-related quality of life, while the incidence of anemia was higher in those receiving high-intensity care compared to usual care; factors like male sex and non-European regions were linked to a higher

Eur J Heart Fail

October 2024

* Patients receiving prednisone showed a significant reduction in inflammation as indicated by decreased levels of high-sensitivity C-reactive protein (hsCRP) and a notably lower risk of heart failure worsening, readmissions, or death over 90 days compared to the usual care group.
* While burst steroid therapy improved outcomes like quality of life and reduced heart failure risks, it was associated with more adverse events like hyperglycemia, indicating a need for larger studies to confirm these findings and further assess safety